LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced an expansion of its collaboration with The University of Texas MD Anderson Cancer Center and pharmaceutical manufacturer GSK on an ongoing clinical trial evaluating its proprietary compound LB-100 in combination with GSK’s Dostarlimab for the treatment of ovarian clear cell cancer. The trial, initiated in January 2024 and led by Amir Jazaeri, MD, at MD Anderson, has added a second site at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University under the direction of Emily M. Hinchcliff, MD, MPH, and is expected to double enrollment to 42 patients following completion of its initial 21-patient target. The company also expects data from the initial cohort to be presented in the first half of 2026.
To view the full press release, visit https://ibn.fm/g1b2t
At a glance
- Company
- LIXTE Biotechnology Holdings, Inc.
- Ticker
- NASDAQ: LIXT
- Announcement
- Expansion
Key figures
- Initial enrollment target
- 21 patients
- Expected enrollment after expansion
- 42 patients
People
- Amir Jazaeri, MDLeads the trial at MD Anderson
- Emily M. Hinchcliff, MD, MPHDirects the trial at the Northwestern site
Products and programs
About LIXTE Biotechnology Holdings, Inc.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
LIXTE’s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE’s new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer.
Additional information about LIXTE can be found at https://lixte.com/
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to LIXT are available in the company’s newsroom at https://ibn.fm/LIXT
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
In brief
LIXTE Biotechnology Holdings says its ovarian clear cell cancer study of LB-100 alongside GSK’s dostarlimab will add a second clinical site. The additional location is the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, where Emily M. Hinchcliff will oversee the work. Amir Jazaeri leads the existing study at The University of Texas MD Anderson Cancer Center. LIXTE says the change is expected to increase planned enrollment to 42 after the original 21-patient group is completed. The trial began in January 2024, and the company anticipates that findings from the initial group will be presented during the first half of 2026. The study evaluates the combination as a treatment for ovarian clear cell cancer.
Key takeaways
- The study adds Northwestern University’s Robert H. Lurie Comprehensive Cancer Center as a second site.
- LIXTE expects enrollment to reach 42 patients after completion of the initial 21-patient target.
- The company anticipates presentation of initial-cohort findings in the first half of 2026.
- The trial evaluates LIXTE’s LB-100 with GSK’s dostarlimab for ovarian clear cell cancer.
